Ninth Annual Biotechnology Investor Conference, November 8, Features
Private and Small to Mid-cap Public Growth Companies
Renowned Investment Banker and Biotechnology Company Start-up Leader
Stelios Papadopoulos, PhD Provides Keynote Address
BOSTON, Oct. 16 /PRNewswire/ -- The Massachusetts Biotechnology Council's ninth annual MASS Opportunities Investor Conference, New England's largest biotechnology investor forum, will explore investment trends and opportunities in life sciences, with a focus on public and venture-stage growth companies as well as those poised to join the growth "watch list" in 2008. To register for the event, go to http://www.massbio.org
Noted former investment banker and biotechnology company builder Dr. Stelios Papadopoulos, whose career in the industry spans more than two decades, will provide the keynote address, titled The Declining Role of Innovation in Biotech.
In addition to a long career in investment banking, Dr. Papadopoulos co- founded Exelixis, Inc., Anadys Pharmaceuticals, Inc., and Cellzome, Inc. He is also vice-chairman of the Board of Directors of BG Medicine, Inc. Dr. Papadopoulos holds a Ph.D. in biophysics and an M.B.A. in finance, both from New York University.
The November 8 event will include more than 30 local public and private companies to showcase their technologies and products. Held at the Hilton Boston Logan Airport hotel, the event brings together over 500 CEO's, portfolio managers, venture capitalists, healthcare analysts, and professionals from the academic, clinical, and technology transfer communities who support emerging and developing biotechnology companies.
Some of the participating companies include Acceleron, Alnylam,
Alseres, Arqule, BioVex, Coley, CominatoRx, Critical Therapeutics, Dyax,
Dynogen Pharmaceuticals, Epitome Biosystems Inc., Exact Sciences
Corporation, Genstruct, Gwalth
|SOURCE Massachusetts Biotechnology Council|
Copyright©2007 PR Newswire.
All rights reserved